KROS (Keros Therapeutics) Days Payable: 0.00 (As of Mar. 2026)

What is Keros Therapeutics Days Payable?

Keros Therapeutics KROS +5.47% 30 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Keros Therapeutics ranks worse than 141442.57% on this metric.

Keros Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $1.73 Mil. Keros Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Keros Therapeutics's Days Payable or its related term are showing as below:

KROS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Keros Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Keros Therapeutics Days Payable Related Terms

Keros Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics Days Payable Chart

Keros Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Keros Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

KROS vs RNA, RNAC, ARCT: Days Payable Comparison

For the Biotechnology subindustry, Keros Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keros Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's Days Payable falls into.

Save Embed

30GF Score

Keros Therapeutics Inc KROS

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Keros Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Keros Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (4.602	+	1.967)	/	2 )	/	0	*	365
=	3.2845					/	0	*	365
=	N/A

Keros Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (1.967	+	1.493)	/	2 )	/	0	*	365 / 4
=	1.73					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Keros Therapeutics (KROS) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry.

Is Keros Therapeutics' Days Payable too high?

Keros Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Keros Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Keros Therapeutics' Days Payable compare to RNA and RNAC?

According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #999999 out of 707 companies for Days Payable. This places Keros Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Keros Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keros Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Keros Therapeutics stock overvalued right now?

Keros Therapeutics (KROS) has a current Days Payable of 0.00. The current Days Payable is 0.00. Keros Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies RNA RNAC ARCT NGEN CNTN YDES NERV ELTX CAMP IKT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421

Website https://www.kerostx.com

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

30GF Score

Get the complete analysis for KROS

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.97

Price

View KROS Analysis

See Days Payable data for all stocks →